Tumor necrosis factor-α and muscle wasting: a cellular perspective by Reid, Michael B & Li, Yi-Ping
c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
r
e
s
e
a
r
c
h
 
a
r
t
i
c
l
e
COPD = chronic obstructive pulmonary disease; kDa = kiloDalton; MHCf = adult fast-type myosin heavy chain; NF-κB = nuclear factor-κB; NO =
nitric oxide; ROS = reactive oxygen species; TNF-α = tumor necrosis factor-α; TNFR1 = type 1 TNF-α receptor; TNFR2 = type 2 TNF-α receptor.
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Introduction
TNF-α is a polypeptide cytokine that promotes antitumor
and immune responses [1]. TNF-α has long been associ-
ated with muscle pathology and was originally designated
‘cachectin’ in recognition of its catabolic action. Experi-
mental animals lose muscle mass when treated with
TNF-α  [2,3] or exposed to interventions that elevate
endogenous TNF-α (e.g. sepsis or tumor implantation). In
humans, muscle catabolism has been attributed to TNF-α
in inflammatory diseases that include cancer [4], conges-
tive heart failure [5], AIDS [6], and chronic obstructive pul-
monary disease (COPD) [7]. In the latter case,
malnourished individuals with COPD have elevated serum
levels of TNF-α [8] which may reflect exaggerated produc-
tion by peripheral blood monocytes [9]. Loss of muscle
mass contributes to weakness, fatigue, and loss of mobil-
ity for individuals with COPD and other inflammatory dis-
eases. Despite its potential importance, the effects of
TNF-α on skeletal muscle and the mechanisms of TNF-α
action have remained largely undefined until recently.
Cellular mechanism of TNF-α α action: 
a working model
This commentary outlines the current perspective of the
authors regarding TNF-α effects on differentiated muscle.
Our concepts are summarized in an experimental model
depicted in Figure 1.
In brief, we propose that TNF-α can act directly on muscle
cells to stimulate protein loss, an action mediated by
nuclear factor-κB (NF-κB) which is a transcription factor.
Intermediate steps in TNF-α/NF-κB signaling include stim-
ulation of the type 1 TNF-α receptor (TNFR1) and an
increase in reactive oxygen species (ROS) production via
mitochondrial electron transport. NF-κB appears to
increase activity of the ubiquitin/proteasome pathway,
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which accelerates the regulated degradation of muscle pro-
teins and promotes muscle weakness. Subsequent sec-
tions address major components of the proposed process
and provide a brief overview of the underlying evidence.
TNF-α α and protein loss
The mechanism of TNF-α effects in vivo remains largely
enigmatic, although it has long been recognized that TNF-α
may stimulate catabolism via indirect mechanisms. TNF-α
alters circulating levels of hormones that regulate muscle
growth and affects tissue sensitivity to such factors. TNF-α
also stimulates production of catabolic cytokines and
induces anorexia. Any of these effects could indirectly
promote muscle wasting. Mechanisms by which TNF-α
might directly stimulate catabolism are less clear. One
potential mechanism is by inhibiting myoblast differentiation
[10,11], an action of TNF-α that could limit the regenera-
tive response of satellite cells to muscle injury [12]. A
second mechanism, apoptosis, appears less important
[13,14]. The third mechanism, a direct catabolic effect on
differentiated muscle, is the focus of this commentary. Early
experiments investigated the catabolic action of TNF-α
using excised rodent muscles in vitro. Incubation with sup-
raphysiologic TNF-α concentrations for up to 3 hours
yielded no detectable change in protein breakdown,
leading previous investigators to conclude that TNF-α does
not directly stimulate protein loss [3,15,16].
More recently, cell culture techniques have enabled the
use of longer-term protocols. In the absence of exogenous
anabolic stimuli, TNF-α directly stimulates a time-depen-
dent and concentration-dependent decrement in total
muscle protein content and loss of muscle-specific pro-
teins, including adult fast-type myosin heavy chain (MHCf)
[13,14]. MHCf losses are not accompanied by a change
in synthesis rate [13], suggesting TNF-α stimulates degra-
dation of myofibrillar proteins. Accelerated protein loss
can be induced using TNF-α levels that do not stimulate
cell death, by either apoptosis or necrosis, and are within
the range measured clinically [13,14]. The catabolic
program activated under these conditions thus closely
mimics the changes observed in muscles of cachectic
humans (i.e. fiber atrophy without overt cell death).
Available data suggest that the catabolic response to
TNF-α in cell culture can be overridden by the superimpo-
sition of anabolic stimuli. Guttridge and co-workers [10]
reported that TNF-α did not stimulate MHCf loss in
myotubes that were simultaneously exposed to pharmaco-
logic levels of insulin. More recently, Langen and col-
leagues [17] used a cell culture matrix of collagen IV,
laminin, heparin sulfate proteoglycan, and entactin to
enhance myocyte differentiation. Myotubes grown on this
matrix were refractory to the catabolic effects of TNF-α.
Only marginal changes were seen in total protein content,
MHCf content, or creatine kinase activity.
The TNF-α α/NF-κ κB pathway
TNF-α stimulates a complex array of postreceptor signal-
ing events that evoke pleiotropic, cell-type-specific
responses. At least three major pathways mediate the
cellular response to TNF-α. One pathway stimulates
apoptosis via interaction with the TNF-α-receptor
complex and the Fas-associated protein with death
domain. A second pathway activates Jun-N-terminal
kinases and the transcription factor AP-1. The third
pathway activates NF-κB, a primary mediator of tran-
scriptional control and a major candidate for catabolic
signaling. We [13,14,18,19] and others [10,17,20] have
shown that TNF-α stimulates the activation and nuclear
translocation of NF-κB in skeletal muscle cells. This is a
rapid, dose-dependent response that involves phospho-
rylation and proteasomal degradation of the NF-κB-
inhibitory protein, Iκ-Bα [13]. NF-κB activity in the cell
nucleus peaks within 30 minutes of TNF-α exposure and
then rapidly decays. This transient stimulus alters gene
expression and causes prolonged changes in muscle
protein levels. The contribution of NF-κB was estab-
lished using a dominant negative approach by which
TNF-α activation of NF-κB could be selectively inhibited
[14]. Myotubes derived from this dominant negative cell
line do not exhibit a catabolic response to TNF-α; neither
total protein content nor muscle-specific protein levels
are diminished by prolonged TNF-α stimulation [14].
These findings suggest that NF-κB signaling is essential
for TNF-α-induced catabolism in differentiated muscle
cells. The differentiation process also appears to be
modulated by TNF-α/NF-κB signaling [10,11,17,19].
This represents a second mechanism by which this
pathway could influence muscle adaptation, both during
development and during activation of satellite cells fol-
lowing muscle injury [12].
Figure 1
Proposed events regulating TNF-α-induced muscle catabolism. TNF-α binding to the type 1 TNF-α receptor (TNFR1) stimulates increased
production of reactive oxygen species (ROS) by mitochondrial electron transport, thereby activating nuclear factor-κB (NF-κB). Subsequently, NF-
κB increases activity of the ubiquitin (Ubq)/proteasome pathway, accelerating protein degradation.
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Receptor-mediated signaling: 
oxidants as second messengers
The responses of muscle cells to TNF-α are mediated by
two sarcolemmal receptor populations, TNFR1 (55 kDa)
and type 2 TNF-α receptor (TNFR2) (75 kDa) [21]. Ligand
binding stimulates a complex cascade of postreceptor sig-
naling events that are subtype-specific. While NF-κB may
be activated via either TNFR1 or TNFR2, the existing data
implicate TNFR1 as the receptor subtype by which TNF-α
stimulates loss of muscle protein [22,23]. This pathway
appears to be redox sensitive. Sen and colleagues [20]
used L6 myoblasts to demonstrate that TNF-α activation of
NF-κB is regulated by the glutathione cycle, a primary
mechanism of antioxidant buffering. Buck and Chojkier [2]
have shown that antioxidants and nitric oxide (NO) syn-
thase blockade inhibit muscle wasting in a mouse model of
TNF-α-induced cachexia. In mature myotubes, TNF-α acti-
vation of NF-κB is blunted by catalase, which enzymatically
dehydrates hydrogen peroxide; conversely, exogenous
hydrogen peroxide activates NF-κB in the absence of TNF-
α [18]. ROS thus appear to function as second messen-
gers for TNF-α in skeletal muscle, activating NF-κB either
directly or indirectly. Data from myotube studies indicate
the most likely source of TNF-α-induced ROS is the mito-
chondrial electron transport chain [18]. NO derivatives do
not appear to be intrinsic elements of this pathway. NO
synthase blockade does not affect TNF-α/NF-κB signaling,
and NF-κB is insensitive to NO donors [18].
The ubiquitin/proteasome pathway as
downstream effector
Existing data suggest that TNF-α stimulates muscle cata-
bolism by activating the ubiqutin/proteasome pathway
[24–26]. As reviewed elsewhere [27], the ubiquitin/pro-
teasome pathway degrades the bulk of all intracellular pro-
teins and is responsible for regulated proteolysis in signal
transduction, cell-cycle progression, transcriptional regula-
tion, and antigen presentation. Pathway activity depends
upon coordinated interactions among several enzyme fam-
ilies. These interventions result in tagging of substrate pro-
teins with polymeric ubiquitin chains that mark the protein
for degradation. The marked protein is then degraded by
the 26S-proteasome complex, by an ATP-dependent
process. In catabolic states, the activity of the ubiquitin/
proteasome pathway is increased by upregulation of
selected pathway components [28]. The level of circulat-
ing TNF-α is also elevated in these conditions and is a
potential stimulus for pathway upregulation. Acute, intra-
venous injection of TNF-α causes time-dependent
increases in both free and conjugated ubiquitin [24], and
ubiquitin mRNA [25] in the limb muscles of intact rats. The
limited data currently available suggest that TNF-α acts
directly on muscle fibers to upregulate the pathway.
Llovera et al [26] have shown that ubiquitin mRNA levels
are elevated in excised muscle exposed to TNF-α in vitro.
Preliminary studies suggest the ubiquitin/proteasome
pathway is sensitive to TNF-α signaling events, including
elevated ROS levels and NF-κB activation [29], but this
link has yet to be established formally.
Conclusion
It appears that TNF-α can act directly on mature muscle to
accelerate protein degradation. The cellular mechanisms
that regulate this response are beginning to be under-
stood. The early mediators of TNF-α action (ROS and NF-
κB) are classical components of the inflammatory
response and are sensitive to other ligand/receptor inter-
actions (e.g. interleukin-1 and interleukin-6). Perhaps ROS
and NF-κB represent upstream elements of a common
pathway that integrates catabolic cytokine input to skeletal
muscle. Such a pathway would have obvious clinical rele-
vance, providing potential targets for therapeutic interven-
tions to inhibit or reverse cachexia. Of course, ROS and
NF-κB are ubiquitous signaling elements that mediate a
variety of cellular responses. Treatment of cachexia will
require the identification of one or more downstream
signals that are specific to skeletal muscle. It is our hope
that continued research will establish muscle-specific
targets and define therapeutic approaches by which
cachexia can be prevented.
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